DARATUMUMAB
Light Chain Nephropathy
Brigham and Women's Hospitalmonoclonal_antibodyActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Light Chain Nephropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Brigham and Women's Hospital | Phase 3 | BB |
cc-5013 National Cancer Institute (NCI) | Phase 3 | B |
Thalidomide Margarida Magalhaes-Silverman | Phase 2 | B |
Inno-206 Margarida Magalhaes-Silverman | Phase 2 | B |
ETOPOSIDE Margarida Magalhaes-Silverman | Phase 2 | B |
View all 10 →
Same molecule, other indications
DARATUMUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →